EGFR and non-small cell lung carcinoma: EGFR TKIs are universally accepted as a first-line treatment for advanced NSCLC patients with a sensitizing EGFR mutation. While mutations such as G719A are sensitive to all generations of EGFR-TKI, the effects are unknown for rare compound mutations in EGFR, such as EGFR L833_V834delinsFL.